ECHELON-2, (NCT01777152), 5-YEAR RESULTS OF A RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF FRONTLINE BRENTUXIMAB VEDOTIN + CHP VS CHOP IN PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA
EHA Library, Eva Domingo Domènech,
325266
PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
EHA Library, Anthony R. Mato,
325284
FIRST-MIND: A PHASE IB, OPEN-LABEL, RANDOMIZED STUDY TO ASSESS SAFETY OF TAFASITAMAB OR TAFASITAMAB + LENALIDOMIDE IN ADDITION TO R‑CHOP IN PATIENTS WITH NEWLY DIAGNOSED DLBCL
EHA Library, David Belada,
325256
PIRTOBRUTINIB (LOXO-305), A NEXT GENERATION, HIGHLY SELECTIVE, NON-COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED MCL, WM AND OTHER NHLS: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
EHA Library, Nirav N Shah,
325260
CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING CONVENTIONAL THIRD-LINE THERAPY: A MULTICENTER, RETROSPECTIVE, REAL-WORLD STUDY IN THE UNITED KINGDOM
EHA Library, Christopher Fox,
325299